Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.
about
In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosisClinical Translation of Nanomedicine.Update on antifungal therapy.Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulationsSafety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits.Differential antifungal activity of isomeric forms of nystatinNew investigational antifungal agents for treating invasive fungal infections.Antifungal pharmacodynamics: review of the literature and clinical applications.Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbitsIn vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolatesLiposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in miceActivity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infectionsLiposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.In vitro and in vivo evaluation of antifungal agents.Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01.Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins.Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma.Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin.New agents for the treatment of systemic fungal infections--current status.Effects and Mechanisms of Action of Polyene Macrolide Antibiotic Nystatin on Babesia gibsoni In Vitro
P2860
Q28369524-4C436E74-308A-4FF9-8DA3-C46F660CF193Q30355939-C236C75E-BAAD-4AEC-8D8E-14C22ECFFA2FQ33648695-85158AEE-29D1-4B81-836B-6563C4DB7DE6Q33693450-30AD7F9E-C532-4849-80AD-B1583CA9724AQ33977852-8DF28C45-AD2F-4E10-80A5-F8C494645D3BQ33979132-087A3B74-0B58-42FB-B99A-8C7F6045A013Q33983112-97CFFB64-61C7-4C10-92C7-E4C6B8EDD7C5Q34075014-4E8A7416-535E-4E4E-92A3-78DCE8805715Q34083129-0469BACD-66E1-44AA-AD3B-1C89C00FFEA6Q34229980-B3A1EB94-D8A6-406E-8783-9360DFC2FE6BQ34452652-D565E5CD-172A-4471-9C95-431543283A26Q35126170-A50B52C9-C8F8-4198-B40C-15A5BF0F699EQ35136440-F8BF8AF2-07BC-4AF2-A64A-8784BFF74CCFQ35138591-99A154E5-D613-40FB-B4E3-29E1D3728068Q35562602-317CED13-6ECD-42F5-8005-3A2CB0115FCEQ37625418-03A5A883-95D1-4F17-BE08-205BC42DC1FAQ38223673-468A4FAA-61D2-4588-9387-C09ECA692F0FQ38300347-79BAF4C0-4666-4583-AE32-1436756A2195Q39470726-29B5A448-2177-40E2-BE00-CB322E47C1C1Q39558179-939337BB-C43E-4B35-8F17-6B6306D833A0Q39784830-649A80C0-EAD4-4792-BE4B-63D16D1977ABQ41846759-BFE0A9BF-B892-48D8-96ED-97CCFED0AAC5Q44837755-D1FB8596-E574-40CD-9847-1C1BB9B473F6Q46576615-3D11C200-86EB-4509-831C-C81530396FC9Q58206592-240EC19C-7948-4792-AEBD-63D5CB12DE4F
P2860
Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Formulation, toxicity, and ant ...... gent for systemic candidiasis.
@en
Formulation, toxicity, and ant ...... gent for systemic candidiasis.
@nl
type
label
Formulation, toxicity, and ant ...... gent for systemic candidiasis.
@en
Formulation, toxicity, and ant ...... gent for systemic candidiasis.
@nl
prefLabel
Formulation, toxicity, and ant ...... gent for systemic candidiasis.
@en
Formulation, toxicity, and ant ...... gent for systemic candidiasis.
@nl
P2093
P2860
P356
P1476
Formulation, toxicity, and ant ...... gent for systemic candidiasis.
@en
P2093
G Lopez-Berestein
L A Gunner
R L Hopfer
R L Juliano
P2860
P304
P356
10.1128/AAC.31.12.1897
P407
P577
1987-12-01T00:00:00Z